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[Abstract]　Objective　The present study aims to investigate the effect of single-nucleotide polymorphisms (SNP) －705T>C and 
－603T>A in the P1 promoter region of human insulin-like growth factor I (IGF-I) gene on promoter activity. Methods　A total of 152 healthy 
volunteers were recruited for the present study. The peripheral blood samples were obtained through venipuncture. The total genomic DNA of each 
blood sample was extracted using the genomic DNA extraction kit. Genotyping of SNP －705T>C and －603T>A in each volunteer was performed 
based on restriction fragment length polymorphism (RFLP) analysis, and the frequencies of each genotype were statistically analyzed. P1 promoter 
haplotypes and their frequencies were analyzed by PHASE v2.1 software program. Luciferase reporter gene assays were adopted to determine 
the difference among activity of different promoter haplotypes. Results　The total genomic DNA of each volunteer was successfully extracted. 
Genotyping of SNP －705T>C and －603T>A was also carried out. The genotype frequencies of －705T/T, －705T/C, and －705C/C were the 
same as those of －603T/T, －603T/A, and －603A/A, which were 43.4%, 45.4%, and 11.2%, respectively. The frequencies of allelic gene －705T 
and －705C were the same as those of -603T and －603A, which were 66.1% and 33.9%, respectively. A complete linkage disequilibrium between 
SNP －705T>C and －603T>A was observed. Moreover, these two SNPs only comprised two types of promoter haplotypes, including －705T/－603T 
(66.1%) and －705C/－603A (33.9%). The results of reporter gene assays showed that the activity of －705C/－603A P1 promoter haplotype was 
significantly higher than that of －705T/－603T haplotype. Conclusion　SNP －705T>C and －603T>A in the P1 promoter field of human IGF-I 
gene can affect the activity of the P1 promoter.
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人胰岛素样生长因子-I基因P1启动子区域单核苷酸多态性－705T>C和－603T>A对启动
子活性的影响
黄伟，邓亮生，王玉丽，高钟镐，宋影文，陈晓旋，冯来武，郭凯琪
[摘要]　目的　探讨人胰岛素样生长因子-I(IGF-I)基因P1启动子区域单核苷酸多态性(SNP)－705T>C和－603T>A
对启动子活性的影响。方法　招募152名健康志愿者参与本研究，取静脉血样品，使用基因组DNA提取试剂盒从血样
中提取全基因组DNA。通过限制片段长度多态性分析(RFLP)，对每名志愿者的SNP－705T>C和－603T>A进行基因分
型，统计各基因型的频率。使用PHASE v2.1软件程序分析P1启动子单体型的类型和频率。通过荧光素酶报告基因测定
不同P1启动子单体型的活力差异。结果　成功提取了每名志愿者的全基因组DNA并测定了SNP －705T>C和－603T>A
的基因型。基因型－705T/T、705T/C、－705C/C的频率分别与－603T/T、－603T/A、－603A/A相同，分别为43.4%、
45.4%、11.2%。等位基因－705T、－705C的频率分别与－603T、－603A相同，分别为66.1%、33.9%。SNP －705T>C 
和－603T>A 之间存在完全的连锁不平衡，其组成的P1启动子单体型只有－705T/－603T和－705C/－603A两种，频率
分别为66.1%和33.9%。报告基因分析结果表明，P1启动子－705C/－603A单体型的活力显著高于－705T/－603T单体
型。结论　人IGF-I基因P1启动子区域SNP －705T/C和－603T/A能够影响P1启动子的活性。
[关键词]　单核苷酸多态性；人胰岛素样生长因子-I；荧光素酶；基因，报告
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Insulin-like growth factor I (IGF-I) is a key growth 
promoting mediator, which functions in both endocrine and 
paracrine systems
[1]. Firstly, IGF-I in the circulation is produced 
by the liver under the stimulation of growth hormone(GH). 
The GH, insulin-like growth factor (IGF), IGF binding proteins 
and their receptors form a GH-IGF axis for regulation of 
cellular proliferation and differentiation. Secondly, the paracrine 
action of IGF-I promotes cellular proliferation and potential 
tumorigenicity at cellular level. Circulating concentration of 
IGF-I is a strong risk factor for various cancers, particularly 
prostate and breast cancers
[2-5]. In addition, the association is 
also mounting for colorectal and lung cancers
[6-7]. 
IGF-I is encoded by IGF-I gene which resides on 
chromosome 12 and consists of six exons and five introns
[8-11]. 
The mature IGF-I protein is encoded by exon 3 to 6. Exon 
2 undergoes alternative splicing which results in generation 
of two forms of mature mRNA (by exon 1-3-4-5/6 or exon 
2-3-4-5/6). Interestingly, exon 1 and exon 2 have their 
own unique promoters, promoter 1 (P1, located upstream 
of exon 1) and promoter 2 (P2, located in intron 1), with 
different transcription starting sites, and the two different 
transcripts generated are commonly referred as class 1 and 
class 2 transcripts, respectively
[12-13]. In animal models, the 
regulation of IGF-I expression seems to be related to variation 
of transactivation activity rather than that of mRNA stability of 
different transcripts
[14-16]. 
It is well known that genetic polymorphism of human 
genome sequence is a common phenomenon in the human 
population. Specially, a lot of single-nucleotide polymorphisms 
(SNPs) have been identified in the regulatory region of many 
genes including IGF-I. The SNPs in the promoter region can 
play an important role in the regulation of gene expression. 
Increasing evidences suggest that SNPs in promoter regions 
can affect gene transcription so as to lead to changes in gene 
expression levels
[17-18]. 
In this study, we genotyped the SNPs －705T>C 
(rs5742612) and －603T>A (rs2288377) in IGF-I P1 promoter 
region in a Chinese population to infer the P1 promoter 
haplotypes. Subsequently, we further investigated the functional 
effect of the －705T>C and －603T>A polymorphisms on 
promoter activity by dual-luciferase reporter assay in SK-N-MC 
and 22RV-1cells. 
1  Materials and methods  
1.1　Genomic DNA extraction　The EDTA anticoagulated 
peripheral blood samples were collected from 152 healthy 
Chinese volunteers by venipuncture. All volunteers were well 
informed and agreed to participate in this study. The blood 
samples were centrifugalized at 18℃ at 3500×g for 10 minutes. 
The total genomic DNA of each sample was extracted by the 
AccuPrep Genomic DNA Extraction Kit (Bioneer, Korea) 
according to the manufacturer's instruction. DNA integrity and 
quantity were confirmed by agarose gel electrophoresis.
1.2　Genotyping of SNPs －705T>C and －603T>A in P1 
promoter　Genotyping of －705T>C and －603T>A was 
performed through restriction fragment length polymorphism 
(RFLP) assay. The same primer pairs, but different types of 
restriction enzymes (Table 1), were used to genotype SNPs 
－705T>C and -603T>A since these two polymorphisms 
were located only 101 bp apart (Figure 1). Each DNA sample 
was subjected to PCR using the following primers. Forward1: 
5'-GGCATAGTCTTTGCCTCATCG-3' and Reverse 1: 
5'-AAAGGAATATGGGGGATGGG-3'. The 297bp fragment 
(from －813 to －517, translation start site as position +1) 
of the experimental volunteers was amplified by AmpliTaq 
Gold DNA Polymerase (Applied Biosystems, USA) according 
to the following reaction conditions:  denature at 96℃ for 
15 minutes followed by 35 cycles of 96℃ for 30 seconds, 
53℃ for 45 seconds and 72℃ for 30 seconds, and then a final 
extension at 72℃ for 10 minutes. Subsequently, PCR products 
were subjected to restriction digestion by Bsl I and Ahd I 
(New England Biolabs, USA), respectively.  The digested PCR 
products were visualized by separating the DNA in a 2% agarose 
gel stained by ethidium bromide. In addition, PCR fragments 
were directly sequenced to validate the genotyping results in 
10% random samples using the above primers and BigDye 
Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, 
USA). 
1.3　Construction of promoter haplotype reporter plasmids
　Promoter haplotypes fragment carrying －705T/－603T 
or －705C/－603A were amplified from corresponding 
genomic DNA samples by PCR using Pfu DNA polymerase 
(Promega, USA) and the following primers. Forward2:5'-
AGCAGATCTAGGAAATGAGATCACACC-3'; Reverse2: 
Fig. 1　Location schematic diagram of SNPs －705T>C and －603T>A in promoter region of human IGF-I gene
Two different promoters (P1 and P2) reside 5' to exon 1 and exon 2, respectively. SNPs －705T>C and －603T>A are located in the P1 
promoter. Translation start site was defined as position +1 
5' 3'
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5'-AGCAAGCTTGCTTCTGAAGTACAAAGTCT-3'. A BglⅡ 
restriction site (underlined) was induced at the 5' end of the 
Forward2 primer, and a HindⅢ restriction site (underlined) 
was induced at the 5' end of the Reverse2 primer. The PCR 
amplification reaction conditions were as follows: denature 
at 95℃ for 2 minutes, followed by 35 cycles of 95℃ for 30 
seconds, 58℃ for 45 seconds and 72℃ for 2 minutes, and then 
a final extension at 72℃ for 10 minutes. The amplified 732bp 
fragments were purified by QIAquick PCR Purification Kit 
(Qiagen, Germany) and then subjected to double digestion 
with BglⅡ and HindⅢ restriction enzymes. The digested 
PCR products were purified by QIAquick Gel Extraction 
Kit (Qiagen, Germany), and then ligated in the purified 
promoterless pGL4.10 reporter vector (Promega, USA) 
with BglⅡ and HindⅢ double digestion through cloning 
procedures. The sequence of cloned promoter fragment was 
confirmed by the BigDye Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems, USA). These two constructed plasmids 
were called as pTT or pCA . Finally, the constructed plasmids 
were prepared for transfection by QIAfilter Plasmid Midi Filter 
Kit (Qiagen, Germany). 
1.4　Cell culture and transient transfection　SK-N-MC and 
22RV-1 cell lines were purchased from ATCC (USA), and were 
cultured with the appropriate medium (MEM medium for SK-N-
MC, RPMI1640 medium for 22RV-1) with the 10% fetal bovine 
serum (GibcoBRL, USA) in the cell incubator at 37℃. Sub-
culture was carried out when cells grew to about 80% confluence. 
Cells were plated in a 24-well multi-plate at the expected 
density (8×10
4 cells/well for SK-N-MC, 4×10
4 cells/well 
for 22RV-1) in 0.5ml medium without antibiotics. After cells 
grew to about 80% confluence, SK-N-MC cells transfection 
was carried out by SuperFect Transfection Reagent (Qiagen, 
Germany), and 22RV-1 cells transfection was carried out by 
FuGENE 6 Transfection Reagent (Roche, Switzerland). For 
each well, cells were co-transfected with 300ng tested plasmids 
and 1ng pGL4.75 reference plasmids (Promega, USA). The 
reference plasmid pGL4.75 can express Rennila lucerase under 
the drive of its CMV promoter, and was used as an internal 
control to correct the transfection efficiency. 
1.5　Dual-luciferase reporter gene assay　After transfection 
for 36-48 hours, dual-luciferase reporter assay was performed 
by the Dual-Luciferase Reporter Assay System (Promega, 
USA). Firstly, the medium in each well was removed, and then 
the cells in each well were gently rinsed once with 1ml PBS 
buffer. After the rinse, PBS was completely removed, 100μl of 
1×Passive Lysis Buffer were added in each well, and then the 
plate was gently rocked at room temperature for 30 minutes 
to allow cell lysate formation. Secondly, the dual-luciferase 
reporter assay was performed on Lumat LB 9501 luminometer 
(Berthold, Germany) according to following procedures. 20μl 
cell lysate was transferred into a 5ml luminometer tube. Then, 
100µl of LAR II Reagent was added and mixed by pipetting 
2 times, and then, immediately, the tube was placed in the 
luminometer to measure firefly luciferase activity for 5-10 
seconds. Subsequently, 100µl of Stop & Glo Reagent was added 
and mixed by pipetting 2 times, and then the Renilla luciferase 
activity was immediately measured for 5-10 seconds. Finally, 
for each well, the activity of firefly luciferase was normalized 
to that of Renilla luciferase. Each experiment was performed in 
triplicate.  
1.6　Statistical analysis　Promoter haplotypes were 
determined by PHASE v2.1 program
[19-20] according to the 
SNPs genotypes data. Reporter assay data represent the mean 
± standard deviation (SD). Statistical analysis was performed 
with SPSS v 13.0 software. Differences between groups 
were evaluated with Student's t test. P<0.05 was considered 
statistically significant.
2  Results
2.1　Genotypes and alleles frequencies of SNPs －705T>C 
and －603T>A　To screen the SNPs in the proximal region 
of P1 promoter, genomic DNA sequencing in 1kb region of 
P1 promoter in 24 random samples was performed. Moreover, 
SNPs screening results were blast to those SNPs existing in 
IGF-I gene in the dbSNP database (http://www.ncbi.nlm.
nih.gov/snp/), and no new SNPs were found. However, it was 
found that －705T>C and －603T>A are the most common 
two polymorphisms in this region. We further determined the 
frequencies of genotypes and alleles of the two above SNPs in 
Chinese population. Genotyping of the above two SNPs in 152 
healthy volunteers was performed by PCR-RFLP method. The 
Tab. 1　Restriction enzymes and restriction fragment length in the RFLP analysis of SNPs －705T>C and －603T>A
SNPs Enzymes Digestion Tm (℃) Genotypes Restriction fragment length (bp)
－705T>C Bsl I 55 T/T 215+82
T/C 215+183+32+82
C/C 183+32+82
－603T>A Ahd I 37 T/T 166+131
T/A 166+131+82+84
A/A 131+82+84Med J Chin PLA, Vol. 37, No. 1, January 1, 2012  　37
297bp length fragment carrying these two SNPs was amplified 
from each DNA sample by PCR, and then was subjected to 
RFLP analysis (Table 1). Finally, the frequencies of genotypes 
and alleles were calculated according to genotyping results 
(Table 2). The genotype frequencies of －705T/T (43.4%), 
－705T/C (45.4%) and －705C/C (11.2%) were the same as those 
of －603T/T, －603T/A and －603A/A, respectively. In addition, 
the allele frequencies of －705T (66.1%) and －705C (33.9%) 
were the same as those of －603T and －603A, respectively.
2.2　Haplotypes distribution of IGF-I P1 promoter　
From the genotyping results of each sample, it was found 
that －705T/T and －603T/T genotypes were concomitant 
and simultaneously existed in one and the same sample. 
Moreover, the same phenomena were found in the combination 
of －705T/C and －603T/A, －705C/C and －603A/A, 
respectively. Furthermore, the PHASE v2.1 program was used 
to determine P1 promoter haplotypes which were dependent 
on SNPs －705T>C and －603T>A, and only two out of 
four possible haplotypes (－705T/－603T and －705C/
－603A) were observed in Chinese population in this 
study. Meanwhile, it has also demonstrated that there was a 
complete linkage disequilibrium between SNPs －705T>C 
and －603T>A (－705T and －603T, －705C and －603A). 
The frequency of －705T/－603T promoter haplotype (66.1%, 
n=201) was almost two times as much as that of －705C/
－603A (33.9%, n=103), which was consistent with the above 
results of genotypes and alleles frequencies. According to 
the type of P1 promoter haplotype carried, individuals were 
stratified into 3 categories including those carrying －705T/
－603T alone, carrying both －705T/－603T and －705C/
－603A, and carrying －705C/－603A alone, with the individual 
frequency of 43.4%, 45.4% and 11.2%, respectively (Table 3). 
Tab. 2　Frequency distribution of genotype and allele of SNPs －705T>C and －603T>A in Chinese population
SNPs Genotypes or alleles Cases Frequency (%)
Genotypes frequency
  －705 T/T 66 43.4
T/C 69 45.4
C/C 17 11.2
  －603 T/T 66 43.4
T/A 69 45.4
A/A 17 11.2
Alleles frequency
  －705 T 201 66.1
C 103 33.9
  －603  T 201 66.1
A 103 33.9
Tab. 3　Frequency distribution of individuals carrying different IGF-I P1 promoter haplotype
Individual type Carried promoter haplotype Cases Frequency (%)
1 －705T/－603T (Only) 66 43.4
2 －705T/－603T and －705C/－603A (Both) 69 45.4
3 －705C/－603A(Only) 17 11.2
2.3　Effect of －705T>C and －603 T>A on promoter 
activity　Dual-luciferase reporter gene assays were performed 
to investigate the effect of SNPs －705T>C and －603T>A on 
P1 promoter activity of IGF-I gene. Because －705T>C and 
－603T>A only existed in －705T/－603T or －705C/
－603A P1 promoter haplotype, comparison of promoter 
activity were performed between only these two promoter 
haplotypes in this study. By molecular cloning techniques, 
these two promoter haplotypes fragments were amplified from 
genomic DNA samples, and then were cloned into the upstream 
of luciferase reporter gene in the promoterless pGL4.10 
reporter vector. Subsequently, the activities of these two 
promoter segments were compared through luciferase reporter 
assays in 22RV-1 and SK-N-MC cells. According to luciferase 
assays results (Figure 2), it was suggested that the activities of 
－705T/－603T promoter haplotype were significantly lower 
than those of －705C/－603A haplotype in the above two cell 
lines (P<0.05). 
3　Discussion
Circulating concentration of IGF-I is programmed by 
both genetic and non-genetic factors
[21] Non-genetic factors 
include age, sex, nutritional status, anthropometry, hormonal/
drug exposure and reproductive history
[22-24].However, genetic 
factors account for a larger extent of the population variance of 
IGF-I than non-genetic factors. From family and twins studies, 
a remarkably high degree of heritability has been reported for 
blood concentration of IGF-I (up to 70%)
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effect played an even stronger role and accounted for more 
than 80% of the variance of population IGF-I concentrations in 
children and infants
[27-28]. 
SNPs －705T>C and －603T>A were important two 
variations in the IGF-I P1 promoter region, and may play a key 
role in the gene regulation of IGF-I. So，it is very necessary to 
directly characterize the effect of these two polymorphisms on 
P1 promoter activity. According to genotyping results, it was 
directly inferred that the T and C alleles at the －705 position 
were strongly linked to the T and A alleles at the －603 position, 
respectively. The subsequently computational analysis by PHASE 
v2.1 program further confirmed that there was a complete linkage 
disequilibrium between －705T>C and －603T>A, and these 
two SNPs only exist in either －705T/－603T or －705C/
－603A promoter haplotype. Moreover, in Chinese population, 
－705T/－603T promoter haplotype was predominant, and the 
frequency of －705T/－603T haplotype was almost two times 
as much as that of －705C/－603A haplotype. Specially, the 
individuals only carrying －705C/－603A haplotype accounted 
for only 11.2% of Chinese population (Table 3). Further, 
luciferase assay results demonstrated that the activity of 
－705T/－603T promoter haplotype was significantly lower than 
that of －705C/－603A haplotype (P<0.05). It was suggested 
that SNPs －705T>C and －603T>A could really affect the 
activity of P1 promoter, and this maybe become a potential factor 
which affect the individual difference of genetic concentration 
of circulating IGF-I protein in population. As we know, the 
individuals with cancer susceptibility account for only a very 
small proportion in total human population, and the high IGF-I 
serum level in human body is a risk factor for various cancers. 
According to our research results, it can be inferred that those 
individuals carrying －705C/－603A haplotype alone had high 
susceptibilities to various cancers.
In summary, we have shown that SNPs －705T>C and 
－603T>A in the IGF-I P1 promoter affect promoter activity. 
These two polymorphisms can serve as good candidates for 
association study between these two SNPs and individual 
genetic level of circulating IGF-I protein, or for case-control 
study to investigate associations between these two SNPs and 
susceptibility to various cancers.
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